CJC-1295 vs Ipamorelin
CJC-1295 and ipamorelin are two of the most referenced growth-hormone peptides, and they are often mentioned in the same breath because they are commonly paired. Importantly, they act on two different receptors — CJC-1295 on the GHRH receptor and ipamorelin on the ghrelin receptor. This comparison outlines how each works and why researchers combine them.
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Class | Synthetic GHRH (growth-hormone-releasing hormone) analog | Selective growth-hormone secretagogue (ghrelin/GHS-R agonist) |
| Primary mechanism | Binds the GHRH receptor to increase GH pulse amplitude | Binds the ghrelin receptor to trigger GH release with minimal cortisol or prolactin |
| Receptor target | GHRH receptor | Ghrelin receptor (GHS-R) — a different receptor |
| Reported half-life | DAC version ~6-8 days; no-DAC (Mod GRF 1-29) ~30 minutes | Short (~2 hours), producing a pulsatile release |
| Reported research dosing | No-DAC often ~100 mcg per dose; DAC dosed weekly in references | ~100-300 mcg per dose |
| Route / frequency | Subcutaneous; DAC ~1-2x/week, no-DAC 1-3x/day | Subcutaneous; often 1-3x/day |
| Regulatory / anti-doping status | Research-use-only, not FDA-approved; WADA Prohibited (S2) | Research-use-only, not FDA-approved; WADA Prohibited (S2) |
| Best studied for | Sustaining and amplifying natural GH pulses | A clean, selective GH pulse with a favorable side-effect profile in references |
CJC-1295
CJC-1295 is referenced for extending and amplifying natural growth-hormone pulses, with a DAC form that acts for days and a no-DAC form (Mod GRF 1-29) that clears within about half an hour.
Full CJC-1295 profile →Ipamorelin
Ipamorelin is referenced as one of the more selective GH secretagogues, prompting a GH pulse through the ghrelin receptor with little effect on cortisol or prolactin.
Full Ipamorelin profile →The bottom line
Because CJC-1295 acts on the GHRH receptor and ipamorelin acts on the ghrelin receptor, research references often describe them as synergistic rather than interchangeable, which is why they are commonly studied as a pair. Both are research-use-only, are not approved for human use, and are prohibited in sport. This is educational information, not medical advice.
Educational summary only. Dosing and effects describe how these compounds appear in the research literature — not a recommendation for human use. For laboratory research use only.
CJC-1295 vs Ipamorelin FAQ
What is the difference between CJC-1295 and ipamorelin?
CJC-1295 is a GHRH analog that raises the amplitude of growth-hormone pulses through the GHRH receptor, whereas ipamorelin is a selective ghrelin-receptor (GHS-R) agonist that triggers a GH pulse with minimal cortisol or prolactin. They act on two different receptors.
Should you combine CJC-1295 and ipamorelin?
Because they target different receptors, the two are frequently studied together in the research community for a larger, more natural-looking GH pulse. Both are research-use-only and unapproved, though, and there is no controlled human safety data for the combination — this is not medical advice.
What is the difference between the DAC and no-DAC versions of CJC-1295?
The DAC (Drug Affinity Complex) version binds albumin and stays active for roughly a week, giving a steady GH increase, while the no-DAC form (often called Mod GRF 1-29 or CJC-1295 without DAC) clears in about 30 minutes and is used to mimic a sharper pulse.
Are CJC-1295 and ipamorelin approved?
Neither is approved by the FDA for human use; both are handled as research-use-only compounds and both appear on the WADA Prohibited List under S2, so they are banned in sport.